Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Neutralizing HIV

By Drug Discovery Trends Editor | July 18, 2011

HIV Vaccine

The fab crystal structure and surface representations from 3BNC60, one of the most potent anti-HIV antibodies isolated in the study. Image: Ron Diskin/Caltech

Each time a virus invades a healthy individual,
antibodies created by the body fight to fend off the intruders. For some
viruses, like HIV, the antibodies are very specific and are generated too
slowly to combat the rapidly changing virus. However, in the past few years,
scientists have found that some HIV-positive people develop highly potent
antibodies that can neutralize different subtypes of the HIV virus.

Now, a study involving researchers at Caltech points to
the possibility of using these neutralizing antibodies in the development of a
vaccine. The paper, published in Science
Express
, describes a group of novel antibodies that were isolated
from HIV-infected individuals using a new cloning approach.

These antibodies are the most potent anti-HIV antibodies targeting
the CD4 binding site—a functional site on the surface of HIV needed for cell
entry and infection—that have ever been identified, says Ron Diskin, a
post-doctoral scholar at Caltech who worked on the paper. David Ho (BS ’74),
scientific director of the Aaron Diamond AIDS
Research Center
in New York, also contributed to the study,
which was led by researchers at Rockefeller
University.

At Caltech, the researchers conducted structural studies
and were able to show, based on similarity to a previously known antibody
(VRC01), that the new antibodies indeed target the CD4 receptor binding site.
CD4 positive cells are the point of HIV infection and where the virus
multiplies.

This study is important for several different reasons,
says Diskin. “First, it provides extremely useful reagents that can be
used for passive immunization to treat infected individuals,” he says.
“Second, it demonstrates that a comparable and highly effective anti-HIV
immune response was elicited in different individuals, which strongly supports
the idea that an effective vaccine will be feasible to develop.”

Next, researchers at Caltech will address the structural
mechanisms that make those antibodies so potent. In fact, they are currently
investigating those structural aspects of the neutralization mechanisms.

“We’re very excited to have
the opportunity to use structural biology to learn what makes these new
antibodies so potent against HIV,” says Pamela Bjorkman, Caltech’s
Delbruck Professor of Biology and a co-author of the study. “We hope that
visualizing how these antibodies interact with HIV proteins will allow the design
of even more potent anti-HIV reagents and provide critical information for
vaccine design.”

SOURCE


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE